A multimodal integration system for early prediction of treatment response to neoadjuvant chemotherapy in patients with breast cancer: a multicenter,prospective study.

A multimodal integration system for early prediction of treatment response to neoadjuvant chemotherapy in patients with breast cancer

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300076999

Enrollment

Unknown

Registered

2023-10-26

Start date

2023-11-01

Completion date

Unknown

Last updated

2023-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

Gold Standard:Pathological result

Index test:A fusion multimodal system based on radiological, pathological and clinical information

Eligibility

Sex/Gender

Female

Age

18 Years to 88 Years

Inclusion criteria

Inclusion criteria: ?Patients were examined by CEM prior to treatment and had available digital pathology slide scan image information. ?Complete surgical pathology results after treatment. ?Clear image quality.

Exclusion criteria

Exclusion criteria: ?There is a history of prior chemoradiotherapy or malignancy. ? Incomplete clinical or pathological information.

Design outcomes

Primary

Measure	Time frame
Area under receiver operating characteristic curve;	—

Secondary

Measure	Time frame
sensitivity;specificity;accuracy;	—

Countries

China

Contacts

Public ContactNing Mao

Yantai Yuhuangding Hospital, Yantai City, Shandong Province

maoning@pku.edu.cn+86 131 0535 1972

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026